Home Biosimilar Antibodies Transmembrane Transporters CD markers Tremelimumab (anti-CTLA-4)
For research use only. Not for use in humans.

Tremelimumab (anti-CTLA-4)

Synonyms: CTLA-4， CD152

Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.

Tremelimumab (anti-CTLA-4)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A202104 Purity: 99.87% Protein concentration: 8.05mg/ml Endotoxin Level: <1 EU/mg
99.87

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes.
References

Product Details

CAS No. 745013-59-6
Molecular Weight 146.4 kDa
Isotype Human IgG2
Source HEK293 Cells
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06680739 RECRUITING Drug: Durvalumab|Drug: Tremelimumab Colorectal Cancer; Endometrial Cancer Vall d'Hebron Institute of Oncology 2022-03-01 PHASE2
NCT06794775 RECRUITING Drug: Nivolumab|Drug: Nivolumab + Ipilimumab Malignant Melanoma Stage III Hildur Helgadottir 2025-07-10 PHASE3
NCT06264180 RECRUITING Drug: Single-agent chemotherapy Advanced Melanoma Replimune, Inc. 2024-07-11 PHASE3
NCT06109272 RECRUITING Drug: Livmoniplimab|Drug: Budigalimab|Drug: Durvalumab|Drug: Hepatocellular Carcinoma AbbVie 2024-01-11 PHASE2; PHASE3
NCT06999707 RECRUITING Drug: Tremelimumab|Drug: Durvalumab HCC - Hepatocellular Carcinoma; Tremelimumab; Durvalumab; Radiotherapy Chang Gung Memorial Hospital 2025-05-22 PHASE2
NCT06999694 RECRUITING Drug: Tremelimumab|Drug: Durvalumab HCC - Hepatocellular Carcinoma; Durvalumab; Tremelimumab; Proton Radiotherapy Chang Gung Memorial Hospital 2025-05-22 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.